Amgen (AMGN): FY26 Q2 earnings call, Aug 4, 2026

Tue, Aug 4Earnings callSpeaker-labelled transcriptAmgen

No Kalshi or Polymarket word markets were listed for Amgen’s Aug 4, 2026 earnings call (FY26 Q2). The transcript is searchable below (quotes of at most 25 words).

Updated

Transcript

quotes of at most 25 words

Speaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.

3 matches for “VESALIUS-CV”; 3 quoted, at least 25 words apart.

Murdo Gordoncompanyprepared

…phase III outcomes data in both primary and secondary prevention. Our landmark VESALIUS-CV trial reinforces that earlier and more intensive LDL-C lowering before cardiovascular events…

Jay Bradnercompanyprepared

…100,000 patient years of exposure. We continue to generate additional insights from VESALIUS-CV, the landmark study of Repatha in pre-event cardiovascular disease. We recently reported…

Jay Bradnercompanyprepared

Also based on the positive VESALIUS-CV study, we recently received a positive CHMP opinion supporting a broader label for Repatha in the E.U. Our cardiovascular…

Agents: this page as TSV at /api/v1/appearances/amgen:2026-08-04:earnings_call · words: /api/v1/brief?appearance=amgen:2026-08-04:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP